Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain.
Analgesic effects of intra-articular botulinum toxin Type B in a murine model of chronic degenerative knee arthritis pain.
复制标题
DOI：
10.2147/jpr.s12520
复制
发表时间：
2010-09-06
影响因子：
2.7
通讯作者：
Mahowald, Maren
中科院分区：
文献类型：
--
作者：
Anderson, Stephanie;Krug, Hollis;Mahowald, Maren
目的：评估关节内肉毒杆菌毒素B型（BoNT/B）在慢性退行性关节炎pain.METHODS和MATERIALS小鼠模型中的镇痛效果：通过将IV型胶原酶关节内注射到左膝，在成年C57 B16小鼠中产生慢性关节炎。诱导关节炎后，治疗组接受关节内BoNT/B。关节炎对照组关节内注射生理盐水或假手术。在关节炎之前、诱导关节炎之后和治疗之后进行疼痛行为测试。疼痛行为测量包括步态障碍分析（自发性疼痛行为）和关节压痛评估（诱发性疼痛反应）。强度测量的能力，把握和cling.RESULTS：视觉步态分析显示关节炎小鼠的步态，改善43%后，关节内的BoNT/B，表现出显着的关节镇痛效果的损害。诱发疼痛反应评分测量的关节压痛随着关节炎诱导而增加，关节内BoNT/B治疗后减少49.5%。在接受关节内生理盐水或假注射的对照组中，没有发现视觉步态评分的改善或诱发疼痛反应评分的降低。关节内BoNT/B是安全的，没有全身效应或四肢无力noticed.CONCLUSIONS：这项研究是第一次报告的关节内BoNT/B镇痛的小鼠模型关节炎疼痛。本研究的结果验证了先前在小鼠模型中使用关节内神经毒素的工作。我们的研究结果表明，慢性退行性关节炎疼痛可以量化在小鼠模型中，通过测量步态障碍，使用视觉步态分析评分（自发性疼痛行为）和关节压痛评分（诱发疼痛反应）。本研究中观察到的关节疼痛减轻与我们的假设一致，即关节内BoNT/B抑制疼痛介质的释放，支持进一步研究这种用关节内神经毒素治疗关节炎疼痛的新方法。
OBJECTIVE: To evaluate the analgesic effectiveness of intra-articular botulinum toxin Type B (BoNT/B) in a murine model of chronic degenerative arthritis pain.METHODS AND MATERIALS: Chronic arthritis was produced in adult C57Bl6 mice by intra-articular injection of Type IV collagenase into the left knee. Following induction of arthritis, the treatment group received intra-articular BoNT/B. Arthritic control groups were treated with intra-articular normal saline or sham injections. Pain behavior testing was performed prior to arthritis, after induction of arthritis, and following treatments. Pain behavior measures included analysis of gait impairment (spontaneous pain behavior) and joint tenderness evaluation (evoked pain response). Strength was measured as ability to grasp and cling.RESULTS: Visual gait analysis showed significant impairment of gait in arthritic mice that improved 43% after intra-articular BoNT/B, demonstrating a substantial articular analgesic effect. Joint tenderness, measured with evoked pain response scores, increased with arthritis induction and decreased 49.5% after intra-articular BoNT/B treatment. No improvement in visual gait scores or decrease in evoked pain response scores were found in the control groups receiving intra-articular normal saline or sham injections. Intra-articular BoNT/B was safe, and no systemic effects or limb weakness was noted.CONCLUSIONS: This study is the first report of intra-articular BoNT/B for analgesia in a murine model of arthritis pain. The results of this study validate prior work using intra-articular neurotoxins in murine models. Our findings show chronic degenerative arthritis pain can be quantitated in a murine model by measuring gait impairment using visual gait analysis scores (spontaneous pain behavior) and joint tenderness scores (evoked pain responses). Reduction of joint pain seen in this study is consistent with our hypothesis of inhibition of release of pain mediators by intra-articular BoNT/B, supporting further investigation of this novel approach to treatment of arthritis pain with intra-articular neurotoxins.